WallStreetZenWallStreetZen

NASDAQ: KYTX
Kyverna Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KYTX

Based on 3 analysts offering 12 month price targets for Kyverna Therapeutics Inc

Min Forecast
$5.00+27.88%
Avg Forecast
$11.67+198.39%
Max Forecast
$20.00+411.51%

Should I buy or sell KYTX stock?

Based on 3 analysts offering ratings for Kyverna Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although KYTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates KYTX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their KYTX stock forecasts and price targets.

KYTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-29
lockedlocked$00.00+00.00%2025-05-27
lockedlocked$00.00+00.00%2025-04-01

1 of 1

Forecast return on equity

Is KYTX forecast to generate an efficient return?

Company
-97.1%
Industry
131.35%
Market
-50.97%
KYTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KYTX forecast to generate an efficient return on assets?

Company
-79.04%
Industry
47.84%
KYTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KYTX earnings per share forecast

What is KYTX's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$3.86
Avg 2 year Forecast
-$3.67
Avg 3 year Forecast
-$3.98

KYTX revenue forecast

What is KYTX's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$37.2M
Avg 2 year Forecast
$39.6M
Avg 3 year Forecast
$157.9M

KYTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KYTX$3.91$11.67+198.39%Strong Buy
CBIO$12.22$25.60+109.49%Strong Buy
CRBU$1.83$3.00+63.93%Buy
MIST$1.97$6.33+221.47%Strong Buy
TVGN$0.84$10.00+1,087.65%Strong Buy
View Top Biotech Stocks

Kyverna Therapeutics Stock Forecast FAQ

Is Kyverna Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: KYTX) stock is to Strong Buy KYTX stock.

Out of 3 analysts, 1 (33.33%) are recommending KYTX as a Strong Buy, 2 (66.67%) are recommending KYTX as a Buy, 0 (0%) are recommending KYTX as a Hold, 0 (0%) are recommending KYTX as a Sell, and 0 (0%) are recommending KYTX as a Strong Sell.

If you're new to stock investing, here's how to buy Kyverna Therapeutics stock.

What is KYTX's earnings growth forecast for 2025-2027?

(NASDAQ: KYTX) Kyverna Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.27%.

Kyverna Therapeutics's earnings in 2025 is -$158,697,000.On average, 5 Wall Street analysts forecast KYTX's earnings for 2025 to be -$166,755,292, with the lowest KYTX earnings forecast at -$175,577,408, and the highest KYTX earnings forecast at -$155,684,401. On average, 5 Wall Street analysts forecast KYTX's earnings for 2026 to be -$158,625,107, with the lowest KYTX earnings forecast at -$182,064,258, and the highest KYTX earnings forecast at -$128,872,088.

In 2027, KYTX is forecast to generate -$171,975,044 in earnings, with the lowest earnings forecast at -$188,551,108 and the highest earnings forecast at -$153,089,661.

What is KYTX's revenue growth forecast for 2027-2029?

(NASDAQ: KYTX) Kyverna Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.

Kyverna Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast KYTX's revenue for 2027 to be $1,607,441,442, with the lowest KYTX revenue forecast at $185,956,368, and the highest KYTX revenue forecast at $3,028,926,517. On average, 1 Wall Street analysts forecast KYTX's revenue for 2028 to be $1,712,528,413, with the lowest KYTX revenue forecast at $1,712,528,413, and the highest KYTX revenue forecast at $1,712,528,413.

In 2029, KYTX is forecast to generate $6,828,490,819 in revenue, with the lowest revenue forecast at $6,828,490,819 and the highest revenue forecast at $6,828,490,819.

What is KYTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: KYTX) forecast ROA is -79.04%, which is lower than the forecast US Biotechnology industry average of 47.84%.

What is KYTX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year KYTX price target, the average KYTX price target is $11.67, with the highest KYTX stock price forecast at $20.00 and the lowest KYTX stock price forecast at $5.00.

On average, Wall Street analysts predict that Kyverna Therapeutics's share price could reach $11.67 by Aug 29, 2026. The average Kyverna Therapeutics stock price prediction forecasts a potential upside of 198.39% from the current KYTX share price of $3.91.

What is KYTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: KYTX) Kyverna Therapeutics's current Earnings Per Share (EPS) is -$3.68. On average, analysts forecast that KYTX's EPS will be -$3.86 for 2025, with the lowest EPS forecast at -$4.06, and the highest EPS forecast at -$3.60. On average, analysts forecast that KYTX's EPS will be -$3.67 for 2026, with the lowest EPS forecast at -$4.21, and the highest EPS forecast at -$2.98. In 2027, KYTX's EPS is forecast to hit -$3.98 (min: -$4.36, max: -$3.54).

What is KYTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: KYTX) forecast ROE is -97.1%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.